RU2593953C2 - Вакцины с живыми бактериальными изолятами для системного введения - Google Patents
Вакцины с живыми бактериальными изолятами для системного введения Download PDFInfo
- Publication number
- RU2593953C2 RU2593953C2 RU2013133856/10A RU2013133856A RU2593953C2 RU 2593953 C2 RU2593953 C2 RU 2593953C2 RU 2013133856/10 A RU2013133856/10 A RU 2013133856/10A RU 2013133856 A RU2013133856 A RU 2013133856A RU 2593953 C2 RU2593953 C2 RU 2593953C2
- Authority
- RU
- Russia
- Prior art keywords
- vaccine
- bronchiseptica
- canine
- infection
- live
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 210
- 238000007910 systemic administration Methods 0.000 title claims abstract description 20
- 230000001580 bacterial effect Effects 0.000 title description 11
- 241000588779 Bordetella bronchiseptica Species 0.000 claims abstract description 140
- 208000015181 infectious disease Diseases 0.000 claims abstract description 74
- 108091007433 antigens Proteins 0.000 claims abstract description 63
- 102000036639 antigens Human genes 0.000 claims abstract description 63
- 239000000427 antigen Substances 0.000 claims abstract description 60
- 239000000654 additive Substances 0.000 claims abstract description 58
- 230000000996 additive effect Effects 0.000 claims abstract description 54
- 241000282465 Canis Species 0.000 claims abstract description 42
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 34
- 241001465754 Metazoa Species 0.000 claims abstract description 31
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims abstract description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 25
- 201000010099 disease Diseases 0.000 claims abstract description 24
- GLDQAMYCGOIJDV-UHFFFAOYSA-N 2,3-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1O GLDQAMYCGOIJDV-UHFFFAOYSA-N 0.000 claims abstract description 23
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract description 23
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 22
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 22
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims abstract description 19
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 18
- 241000700605 Viruses Species 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 18
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 18
- 230000004224 protection Effects 0.000 claims abstract description 15
- 229940082044 2,3-dihydroxybenzoic acid Drugs 0.000 claims abstract description 11
- 125000003118 aryl group Chemical group 0.000 claims description 63
- 101150037081 aroA gene Proteins 0.000 claims description 51
- 239000002671 adjuvant Substances 0.000 claims description 49
- 101100491986 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) aromA gene Proteins 0.000 claims description 43
- 241001167018 Aroa Species 0.000 claims description 41
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 34
- 241001353878 Canine parainfluenza virus Species 0.000 claims description 30
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 19
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 14
- 239000003085 diluting agent Substances 0.000 claims description 12
- 206010022000 influenza Diseases 0.000 claims description 12
- 229940103272 aluminum potassium sulfate Drugs 0.000 claims description 6
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 abstract description 38
- 239000000203 mixture Substances 0.000 abstract description 22
- 230000002238 attenuated effect Effects 0.000 abstract description 21
- 208000002606 Paramyxoviridae Infections Diseases 0.000 abstract description 9
- 230000002829 reductive effect Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 110
- 238000011282 treatment Methods 0.000 description 57
- 238000002255 vaccination Methods 0.000 description 51
- 238000002347 injection Methods 0.000 description 37
- 239000007924 injection Substances 0.000 description 37
- 229940024545 aluminum hydroxide Drugs 0.000 description 33
- 108090000623 proteins and genes Proteins 0.000 description 27
- 150000007523 nucleic acids Chemical class 0.000 description 25
- 108020004707 nucleic acids Proteins 0.000 description 24
- 102000039446 nucleic acids Human genes 0.000 description 24
- 206010011224 Cough Diseases 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 22
- 150000001491 aromatic compounds Chemical class 0.000 description 20
- 229940031348 multivalent vaccine Drugs 0.000 description 20
- 229960005190 phenylalanine Drugs 0.000 description 19
- 229960004799 tryptophan Drugs 0.000 description 18
- 229960004441 tyrosine Drugs 0.000 description 18
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 16
- 241000282324 Felis Species 0.000 description 12
- 206010022095 Injection Site reaction Diseases 0.000 description 12
- 206010030113 Oedema Diseases 0.000 description 12
- 238000012217 deletion Methods 0.000 description 12
- 230000037430 deletion Effects 0.000 description 12
- 230000001105 regulatory effect Effects 0.000 description 12
- 108091026890 Coding region Proteins 0.000 description 10
- 241000588832 Bordetella pertussis Species 0.000 description 9
- 241000282326 Felis catus Species 0.000 description 9
- 101710154606 Hemagglutinin Proteins 0.000 description 9
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 9
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 9
- 101710176177 Protein A56 Proteins 0.000 description 9
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 9
- 239000000185 hemagglutinin Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000012545 processing Methods 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 229960000304 folic acid Drugs 0.000 description 8
- 235000019152 folic acid Nutrition 0.000 description 8
- 239000011724 folic acid Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000005348 Neuraminidase Human genes 0.000 description 7
- 108010006232 Neuraminidase Proteins 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 239000010452 phosphate Substances 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000002269 spontaneous effect Effects 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- SERBHKJMVBATSJ-UHFFFAOYSA-N Enterobactin Natural products OC1=CC=CC(C(=O)NC2C(OCC(C(=O)OCC(C(=O)OC2)NC(=O)C=2C(=C(O)C=CC=2)O)NC(=O)C=2C(=C(O)C=CC=2)O)=O)=C1O SERBHKJMVBATSJ-UHFFFAOYSA-N 0.000 description 6
- 108010061075 Enterobactin Proteins 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- SERBHKJMVBATSJ-BZSNNMDCSA-N enterobactin Chemical compound OC1=CC=CC(C(=O)N[C@@H]2C(OC[C@@H](C(=O)OC[C@@H](C(=O)OC2)NC(=O)C=2C(=C(O)C=CC=2)O)NC(=O)C=2C(=C(O)C=CC=2)O)=O)=C1O SERBHKJMVBATSJ-BZSNNMDCSA-N 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 241000701087 Felid alphaherpesvirus 1 Species 0.000 description 5
- 241000714201 Feline calicivirus Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000012065 filter cake Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000009931 harmful effect Effects 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 238000002559 palpation Methods 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 241000446432 Feline pneumovirus Species 0.000 description 4
- 241000589902 Leptospira Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- -1 aromatic amino acids Chemical class 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 208000013220 shortness of breath Diseases 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000008223 sterile water Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- WTFXTQVDAKGDEY-UHFFFAOYSA-N (-)-chorismic acid Natural products OC1C=CC(C(O)=O)=CC1OC(=C)C(O)=O WTFXTQVDAKGDEY-UHFFFAOYSA-N 0.000 description 3
- PJWIPEXIFFQAQZ-PUFIMZNGSA-N 7-phospho-2-dehydro-3-deoxy-D-arabino-heptonic acid Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@H](O)CC(=O)C(O)=O PJWIPEXIFFQAQZ-PUFIMZNGSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010024264 Lethargy Diseases 0.000 description 3
- 241001293418 Mannheimia haemolytica Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 206010039101 Rhinorrhoea Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 229960001212 bacterial vaccine Drugs 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- WTFXTQVDAKGDEY-HTQZYQBOSA-N chorismic acid Chemical compound O[C@@H]1C=CC(C(O)=O)=C[C@H]1OC(=C)C(O)=O WTFXTQVDAKGDEY-HTQZYQBOSA-N 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000013067 intermediate product Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 208000010753 nasal discharge Diseases 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 241000606646 Anaplasma Species 0.000 description 2
- 241001647374 Chlamydia felis Species 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- NGHMDNPXVRFFGS-IUYQGCFVSA-N D-erythrose 4-phosphate Chemical compound O=C[C@H](O)[C@H](O)COP(O)(O)=O NGHMDNPXVRFFGS-IUYQGCFVSA-N 0.000 description 2
- 101100055841 Danio rerio apoa1 gene Proteins 0.000 description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 description 2
- 241000711475 Feline infectious peritonitis virus Species 0.000 description 2
- 241000714165 Feline leukemia virus Species 0.000 description 2
- 241000701925 Feline parvovirus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000606831 Histophilus somni Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 241000721701 Lynx Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 241000282320 Panthera leo Species 0.000 description 2
- 241000606856 Pasteurella multocida Species 0.000 description 2
- 241000711902 Pneumovirus Species 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- 241000831652 Salinivibrio sharmensis Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229940124590 live attenuated vaccine Drugs 0.000 description 2
- 229940023012 live-attenuated vaccine Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229940051027 pasteurella multocida Drugs 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- GLDQAMYCGOIJDV-UHFFFAOYSA-M 2,3-dihydroxybenzoate Chemical compound OC1=CC=CC(C([O-])=O)=C1O GLDQAMYCGOIJDV-UHFFFAOYSA-M 0.000 description 1
- 241001455214 Acinonyx jubatus Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241001081972 Arctium medians Species 0.000 description 1
- 201000008283 Atrophic Rhinitis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000606660 Bartonella Species 0.000 description 1
- 241001518086 Bartonella henselae Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000879755 Caracal Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000605314 Ehrlichia Species 0.000 description 1
- 241000605312 Ehrlichia canis Species 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 206010056474 Erythrosis Diseases 0.000 description 1
- 101710154643 Filamentous hemagglutinin Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229940124841 Herpesvirus vaccine Drugs 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 241000589929 Leptospira interrogans Species 0.000 description 1
- 241001550390 Leptospira interrogans serovar Canicola Species 0.000 description 1
- 241000589926 Leptospira interrogans serovar Hardjo Species 0.000 description 1
- 241001518154 Leptospira kirschneri serovar Grippotyphosa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 241000282372 Panthera onca Species 0.000 description 1
- 241000282373 Panthera pardus Species 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 241001147389 Panthera uncia Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 241000282374 Puma concolor Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039088 Rhinitis atrophic Diseases 0.000 description 1
- 206010051497 Rhinotracheitis Diseases 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 239000000589 Siderophore Substances 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 101710182223 Toxin B Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- NTGGOTYRTOXKMQ-UHFFFAOYSA-K aluminum;potassium;phosphate Chemical compound [Al+3].[K+].[O-]P([O-])([O-])=O NTGGOTYRTOXKMQ-UHFFFAOYSA-K 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 241000385736 bacterium B Species 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- APGFPQCBDNWQSB-UHFFFAOYSA-N cyclohexa-1,3-diene-1-carboxylic acid Chemical compound OC(=O)C1=CC=CCC1 APGFPQCBDNWQSB-UHFFFAOYSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229940051998 ehrlichia canis Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940066827 pertussis vaccine Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 229960003127 rabies vaccine Drugs 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 208000011479 upper respiratory tract disease Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061425855P | 2010-12-22 | 2010-12-22 | |
| US61/425,855 | 2010-12-22 | ||
| EP11152829.5 | 2011-02-01 | ||
| EP11152829 | 2011-02-01 | ||
| US201161556975P | 2011-11-08 | 2011-11-08 | |
| US61/556,975 | 2011-11-08 | ||
| PCT/IB2011/003100 WO2012085642A1 (en) | 2010-12-22 | 2011-12-21 | Vaccines with live bacterial isolates for systemic administration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2013133856A RU2013133856A (ru) | 2015-01-27 |
| RU2593953C2 true RU2593953C2 (ru) | 2016-08-10 |
Family
ID=43628729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013133856/10A RU2593953C2 (ru) | 2010-12-22 | 2011-12-21 | Вакцины с живыми бактериальными изолятами для системного введения |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8821852B2 (https=) |
| EP (1) | EP2655403A1 (https=) |
| JP (1) | JP6145046B2 (https=) |
| CN (1) | CN103261214B (https=) |
| BR (1) | BR112013015009B1 (https=) |
| CA (2) | CA2821422C (https=) |
| RU (1) | RU2593953C2 (https=) |
| WO (1) | WO2012085642A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106729683B (zh) * | 2016-12-16 | 2019-12-03 | 青岛易邦生物工程有限公司 | 一种猪支气管败血波氏杆菌病疫苗 |
| JP2022520925A (ja) * | 2019-01-04 | 2022-04-04 | ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド | 弱毒化ボルデテラ・ブロンキセプチカ株、当該弱毒化株を含む経口ワクチン並びに前記の製造及び使用方法 |
| EP4061303A1 (en) * | 2019-11-18 | 2022-09-28 | Elanco Us Inc. | Lyophilized cake in straight-walled vial |
| MX2022007578A (es) * | 2019-12-18 | 2022-07-19 | Intervet Int Bv | Vacuna respiratoria oral. |
| EP3909971A1 (en) | 2020-09-28 | 2021-11-17 | Institute of Life Sciences (ILS) | Whole cell livestock vaccine for respiratory diseases |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989005856A1 (en) * | 1987-12-23 | 1989-06-29 | The Wellcome Foundation Limited | Vaccines |
| WO2003060105A1 (en) * | 2001-12-28 | 2003-07-24 | University Of Southern Queensland | Defective entities and uses therefor |
| RU2005124130A (ru) * | 2003-01-29 | 2006-01-20 | Пфайзер Продактс Инк. (Us) | Вакцины для собак против bordetella bronchiseptica |
| CN101575586B (zh) * | 2009-05-31 | 2011-01-19 | 华中农业大学 | 一种支气管败血波氏杆菌基因缺失疫苗及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5955089A (en) * | 1993-04-20 | 1999-09-21 | Uab Research Foundation | Strain selection of pneumococcal surface proteins |
| US5840556A (en) | 1996-05-08 | 1998-11-24 | The United States Of America As Represented By The Department Of Agriculture | Molecular genetic construction of vaccine strains of pasteurellaceae |
| EP0835928A1 (en) * | 1996-10-11 | 1998-04-15 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin | Helicobacter pylori live vaccine |
| US7959929B2 (en) | 2005-04-21 | 2011-06-14 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
| PH12011502633A1 (en) * | 2005-10-07 | 2012-11-12 | Zoetis P Llc | Vaccines and methods to treat canine influenza |
| EP3800244A1 (en) | 2006-03-10 | 2021-04-07 | Institut Pasteur de Lille | Live attenuated bordetella strains as a single dose vaccine against whooping cough |
| EP2134359A4 (en) | 2007-02-23 | 2010-06-16 | Penn State Res Found | USE OF A NONVIRULENT BORDETELLA MUTANT AS LIVING VACCINE VECTOR |
| KR20080082883A (ko) * | 2007-03-09 | 2008-09-12 | 전남대학교산학협력단 | 약독화된 보르데텔라 브론키셉티카 (ｂｂｓ) 균주 및 그의제조 방법, 그를 포함하는 면역원성 조성물 및 그를 이용한포유동물의 ｂｂｓ 감염증을 치료 또는 예방하는 방법 |
| TWI468157B (zh) | 2009-04-29 | 2015-01-11 | Intervet Int Bv | 形成錠劑的方法，進行該方法的系統及包含該錠劑的包裝物 |
-
2011
- 2011-12-21 JP JP2013545520A patent/JP6145046B2/ja active Active
- 2011-12-21 EP EP11815565.4A patent/EP2655403A1/en not_active Withdrawn
- 2011-12-21 CA CA2821422A patent/CA2821422C/en active Active
- 2011-12-21 BR BR112013015009-2A patent/BR112013015009B1/pt active IP Right Grant
- 2011-12-21 WO PCT/IB2011/003100 patent/WO2012085642A1/en not_active Ceased
- 2011-12-21 US US13/995,740 patent/US8821852B2/en active Active
- 2011-12-21 RU RU2013133856/10A patent/RU2593953C2/ru active
- 2011-12-21 CA CA3219727A patent/CA3219727A1/en active Pending
- 2011-12-21 CN CN201180061881.2A patent/CN103261214B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989005856A1 (en) * | 1987-12-23 | 1989-06-29 | The Wellcome Foundation Limited | Vaccines |
| WO2003060105A1 (en) * | 2001-12-28 | 2003-07-24 | University Of Southern Queensland | Defective entities and uses therefor |
| RU2005124130A (ru) * | 2003-01-29 | 2006-01-20 | Пфайзер Продактс Инк. (Us) | Вакцины для собак против bordetella bronchiseptica |
| CN101575586B (zh) * | 2009-05-31 | 2011-01-19 | 华中农业大学 | 一种支气管败血波氏杆菌基因缺失疫苗及应用 |
Non-Patent Citations (2)
| Title |
|---|
| CHLADEK D.W. ET AL. Canine parainfluenza-Bordetella bronchiseptica vaccine immunogenicity. AMERICAN JOURNAL OF VETERINARY RESEARCH. 1981. Vol. 42. No 2. P. 266-270. * |
| MCARTHUR J.D. ET AL. An aromatic amino acid auxotrophic mutant of Bordetella bronchiseptica is attenuated and immunogenic in a mouse model of infection. FEMS MICROBIOLOGY LETTERS. 2003. Vol. 221. P. 7-16. * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014500302A (ja) | 2014-01-09 |
| US20130273100A1 (en) | 2013-10-17 |
| JP6145046B2 (ja) | 2017-06-07 |
| EP2655403A1 (en) | 2013-10-30 |
| CA2821422A1 (en) | 2012-06-28 |
| BR112013015009B1 (pt) | 2020-11-10 |
| CA2821422C (en) | 2024-01-02 |
| CA3219727A1 (en) | 2012-06-28 |
| WO2012085642A1 (en) | 2012-06-28 |
| CN103261214B (zh) | 2016-10-26 |
| RU2013133856A (ru) | 2015-01-27 |
| US8821852B2 (en) | 2014-09-02 |
| CN103261214A (zh) | 2013-08-21 |
| BR112013015009A2 (pt) | 2016-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9409954B2 (en) | Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens | |
| US12514922B2 (en) | Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and infectious bursal disease virus antigens | |
| CA2957472C (en) | Attenuated bovine coronavirus and related vaccines | |
| US11229698B2 (en) | Recombinant non-pathogenic Marek's Disease virus constructs encoding multiple heterologous antigens | |
| AU2016228316A1 (en) | Neisseria meningitidis compositions and methods thereof | |
| RU2593953C2 (ru) | Вакцины с живыми бактериальными изолятами для системного введения | |
| JP2021506782A (ja) | レンサ球菌感染防御のためのワクチン | |
| BR112020011041A2 (pt) | vacina contra a doença de lyme canina | |
| US11439703B2 (en) | Enhanced immune response in porcine species | |
| US9119803B2 (en) | Carious tooth vaccine and preparation method | |
| US20240299528A1 (en) | A dna plasmid sars-corona virus-2/covid-19 vaccine | |
| BR112021013241A2 (pt) | Cepas atenuadas de bordetella bronchiseptica, vacinas orais contendo as cepas atenuadas e métodos de preparação e uso das mesmas | |
| EP2076280B1 (en) | Feline influenza vaccine and method of use | |
| WO2022055375A1 (es) | Vacuna viva recombinante para sars-cov-2 basada en salmonella enteritidis recombinante | |
| BR112018002107B1 (pt) | Uso de um imunomodulador para potencializar resposta imune em espécies suínas | |
| EP3323424A1 (en) | Cyaa polypeptides as immune enhancer |